Feikai Materials: In 2021, the downstream customers of the company’s pharmaceutical intermediate products will continue to increase, and the annual sales will increase significantly_Oriental Fortune Network

Summary

[Feikai Materials: In 2021, the downstream customers of the company’s pharmaceutical intermediate products will continue to increase and the annual sales will increase significantly]The company’s market share of bromoacetonitrile currently has no third-party authoritative statistical information, and the company cannot judge whether it is used for Pfizer and other new crown virus prevention and treatment in specific medicines. In 2021, the downstream customers of the company’s pharmaceutical intermediate products will continue to increase, and the annual sales volume will increase significantly. The company always attaches great importance to the claims of shareholders’ legal rights, and the company has no information that should be disclosed but not disclosed.

Every time the AI ​​Express is sent, some investors ask questions on the investor interaction platform:PfizerThe synthesis of oral drugs requires bromoacetonitrile. The company’s bromoacetonitrile accounts for 70% of the global share. How about the company’s recent sales of bromoacetonitrile?asshareholder, should have this right to know?

　　Feikai material(300398.SZ) stated on the investor interactive platform on January 13 that the company’s market share of bromoacetonitrile currently has no third-party authoritative statistical information, and the company cannot judge whether it is used forPfizerWaiting for the new coronavirus prevention and treatment special medicine. In 2021, the downstream customers of the company’s pharmaceutical intermediate products will continue to increase, and the annual sales volume will increase significantly. The company always attaches great importance to the claims of shareholders’ legal rights, and the company has no information that should be disclosed but not disclosed.

(Article source: Daily Economic News)

Article source: Daily Economic News

Responsible editor: 43

Original title: Feikai Materials: In 2021, the downstream customers of the company’s pharmaceutical intermediate products will continue to increase, and the annual sales volume will increase significantly